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Abstract
BACKGROUND AND AIMS: Although both cancer and stellate cells (PSCs) secrete proangiogenic factors, pancreatic
cancer is a scirrhous and hypoxic tumor. The impact of cancer-PSCs interactions on angiogenesis was analyzed.
METHODS: Expression of periostin, CD31, and α-smooth muscle actin was assessed by immunohistochemistry.
Human PSCs and cancer cells were cultivated under normoxia and hypoxia alone, or in coculture, to analyze the
changes in their angiogenic and fibrogenic attributes, using enzyme-linked immunosorbent assay, immunoblot,
and quantitative polymerase chain reaction analyses and growth of cultured endothelial cells in vitro. RESULTS:
On the invasive front of the activated stroma, PSCs deposited a periostin-rich matrix around the capillaries in the
periacinar spaces. Compared with the normal pancreas, there was a significant reduction in the microvessel density
in chronic pancreatitis (five-fold, P < .001) and pancreatic cancer (four-fold, P < .01) tissues. In vitro, hypoxia in-
creased PSCs' activity and doubled the secretion of periostin, type I collagen, fibronectin, and vascular endothelial
growth factor (VEGF). Cancer cells induced VEGF secretion of PSCs (390 ± 60%, P< .001), whereas PSCs increased
the endostatin production of cancer cells (210 ± 14%, P < .001) by matrix metalloproteinase–dependent cleavage.
In vitro, PSCs increased the endothelial cell growth, whereas cancer cells alone, or their coculture with PSCs, sup-
pressed it. CONCLUSIONS: Although PSCs are the dominant producers of VEGF and increase endothelial cell growth
in vitro, in the peritumoral stroma, they contribute to the fibrotic/hypoxic milieu through abnormal extracellular matrix
deposition and by amplifying endostatin production of cancer cells.
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Introduction
The activated stroma of pancreatic cancer is an important feature
of pancreatic ductal adenocarcinoma (PDAC) and has a significant
impact on patient survival [1]. Pancreatic stellate cells (PSCs) produce
this fibrotic/hypoxic microenvironment in which PDAC cells evolve
[2–5]. Angiogenesis is essential for the growth and survival of solid
tumors [6–8]. Without accompanying neoangiogenesis, tumors cannot
exceed 1 to 2 mm in diameter [6–8]. According to standard reasoning,
primary epithelial tumors that are initially separated from underlying
vessels by the basement membrane eventually become hypoxic as they
outgrow the ambient vascular supply [9,10]. Several artificial models in
which tumor cells are seeded into initially avascular spaces (i.e., subcu-
taneous, cornea pocket, vitreous) prove that hypoxic tumor cells induce
angiogenic in-growth by secretion of neoangiogenic substances such as
vascular endothelial growth factor (VEGF) and angiopoietin 2 [10,11].
Such manipulation of the microenvironment allows further growth of
the initial tumor [10,12,13]. However, recent evidence suggests that
early on, tumor cells grow by co-opting existing host vessels; thus they
start as well-vascularized tumors but later become hypoxic because of a
defensive host response [10,14].
The production of a fibronectin- and type I collagen–rich extracellu-
lar matrix (ECM) is a crucial step in initiation of tumor angiogenesis
[15–18]. Therefore, the early tumor microenvironments is associated
with more stromal cells, enhanced capillary density, and type I collagen
and fibrin deposition [4,13,15,19]. Although tumor cells can secrete
VEGF themselves, stromal and inflammatory cells are the principal
sources of host-derived VEGF [18,20].
We and others have previously shown that 1) the fibrotic stroma
of the diseased pancreas is hypoxic [5,21], 2) pancreatic cancer cells
(PCCs) and PSCs respond to tissue hypoxia with a robust hypoxia-
inducible factor 1α protein increase [5,21], and 3) PSCs produce po-
tent angiogenic substances such as VEGF, basic fibroblast growth factor,
and periostin [3,4,22]. Therefore, it is difficult to explain why PDAC
in humans is so scirrhous, with tissue oxygen tension remaining con-
siderably lower than in the surrounding normal pancreas [5,21]. It also
seems plausible that this already hypovascular microenvironment may
be a reason that antiangiogenic therapies generally fail in PDAC [23].
In this study, we evaluated the fibrogenic and angiogenic responses
of PSCs under hypoxia. To verify our ex vivo observations and in vitro
results at a functional level, we used various models of pancreatic cancer
and stellate cell cocultures to assess their individual and combined ef-
fects on the growth of endothelial cells.
Materials and Methods
Pancreatic Tissues and Human PSCs Cultivation
Tissue collection and preservation were performed as described
previously [24]. Human PSCs were isolated from fibrotic areas of
resected PDAC tissues using the outgrowth method, as described ini-
tially by Bachem et al. [3]. The use of human material for the analysis
was approved by the local ethics committee of the University of
Heidelberg, Germany, and written informed consent was obtained
from all patients.
Human PCC Lines
Colo-357, MiaPaCa-2, Panc-1, and SU86.86 were either pur-
chased from ATCC (Rockville, MD) or received as a kind gift from
Dr. R. S. Metzgar (Durham, NC). The cells were routinely grown in
complete medium (RPMI-1640 supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, and 100 μg/ml streptomycin) at 37°C
and saturated with 5% CO2 in a humid atmosphere.
Immunohistochemistry
Initial hematoxylin + eosin staining was performed to choose tissue
blocks that contained large-enough areas of stroma for further immu-
nohistochemical analysis. Immunohistochemistry (IHC) and quanti-
tative color analysis were performed as described previously [1,4]. In
brief, consecutive sections of normal pancreas (n = 5), chronic pancre-
atitis (CP; n = 20), and PDAC (n = 30) tissues were stained with
α-smooth muscle actin (α-SMA; for PSCs, diluted 1:1500; M0851;
DAKO Cytomation, Hamburg, Germany) and CD31 (for endothelial
cells, diluted 1:50; M0823; DAKO Cytomation) without counter-
staining to yield better quantification of the MVD. A frame of 4 ×
4 mm was marked over the fibrotic area for analysis. Stromal tissue
confined within this frame was then scanned automatically (mean area
evaluated, 14 mm2/section; mean number of 200× magnified fields:
90 per section). Image analysis was carried out using a Zeiss Axiocam
3.1 system and the KS300 3.0 program to evaluate the amount of
PSCs and endothelial cell staining (Zeiss, Jena, Germany). The results
were expressed as percent area positive for CD31/α-SMA in the total
scanned surface. In representative blocks, immunohistochemical anal-
ysis was repeatedwith antiperiostin (1:4000, RD181045050; Biovendor,
Heidelberg, Germany), α-SMA, and CD31 antibodies for demonstra-
tive pictures.
Immunoblot Analysis and Densitometry
Immunoblot analyses of the cell lysates (CLs; for synthesis) and
matching supernatants (SNs for secretion) as well as densitometric
analysis of the blots were performed as described previously [4]. To
demonstrate the interplay between PSCs activity (α-SMA), periostin,
type I collagen, fibronectin synthesis, and secretion, each membrane
was stripped and reblotted consecutively with the specific antibodies.
γ-Tubulin was used to verify equal loading. Antibodies used: type Ia
collagen (1:2000; sc-28657; Santa Cruz Biotechnology, Santa Cruz,
CA), fibronectin (1:10,000; F3648; Sigma Aldrich, Taufkirchen,
Germany), periostin (1:5000; RD181045050; Biovendor), α-SMA
(1:10,000; M0851; DAKO Cytomation), matrix metalloproteinase
12 (MMP-12) antibody (AB19051) and positive control (AG902;
Millipore, Schwalbach, Germany), and γ-tubulin (1:5000; sc-7396;
Santa Cruz Biotechnology). Experiments were repeated three times
using different PSC clones.
Collection of SNs and Enzyme-Linked Immunosorbent Assay
Cells were seeded in six-well plates (PSCs: 200,000 cells per well,
PCCs: 400,000 cells per well) using the appropriate medium, i.e.,
RPMI-1640 with 10% fetal calf serum for PCCs, and stellate cell
medium (1:1 [vol/vol] mixture of Dulbecco’s modified Eagle medium
and Ham’s F12 medium with penicillin 1%, streptomycin 1%, and
10% fetal calf serum) for PSCs. Thereafter, all types of cells were in-
cubated with serum-free stellate cell medium for the indicated periods.
Five types of SNs were produced from sister clones of cells under both
normoxic and hypoxic conditions: 1) Supernatants of PCC lines (Colo-
357, MiaPaCa-2, Panc-1, and SU86.86); 2) Supernatants of PSCs; 3)
Combined SNs of the coculture of PSCs at the bottom of a six-well
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plate and Colo357, MiaPaCa-2, Panc-1, or SU86.86 in the insert of a
coculture system (1 μm pore size; 352102; BD Falcon, Erembodegem,
Belgium). Moreover, two types of exchange SNs were created using
PSCs and PCCs in six-well plates. After 24 hours, the SNswere removed
and used to incubate the reciprocal cells for another 24 hours; 4) Super-
natant of PSCs that was subsequently used to incubate PCCs; 5) Super-
natant of PCCs that was subsequently used to incubate PSCs. Each
experiment was repeated at least three times using different PCC and
PSC clones. All SNs were immediately centrifuged, aliquoted, frozen,
and stored at −80°C until use. For the analyses, the following ELISA kits
were used: VEGF (DVE00), endostatin (DNST0), and ProCathepsin B
(DCATB0), all fromR&DSystems,Wiesbaden-Nordenstadt, Germany.
Cultivation and Use of Primary Human Umbilical Vein
Endothelial Cells
Cells were purchased and cultivated according to the manufac-
turer’s recommendations (HUVEC-pC-12250; Promocell, Heidelberg,
Germany). Five thousand cells were seeded in 100 μl of endothelial
cell growth medium (C-22010; Promocell) supplemented with Supple-
mentMix (C-39215; Promocell) in 96-well plates. Twenty-four hours
later, 100 μl of appropriate SN was added to the cells. Forty-eight hours
later, cell growth was analyzed by MTT assay as described previously
[24]. Experiments were repeated at least four times in different com-
binations using two different human umbilical vein endothelial cells
(HUVECs) and two different PSC clones.
Induction of Hypoxia
Sister clones of cancer cells and PSCs were kept under a hypoxic gas
mixture (0.75% O2, 10% CO2, 89.25% N2) for the indicated periods
as described previously [5,24].
Inhibition of MMPs and Cathepsins B, S, and L
Because no specific MMP-12 inhibitor is commercially available, a
broad-spectrum small-molecule MMP inhibitor (50 μM; ONO4817;
Tocris, Bristol, UK), which also inhibits MMP-12, was used in cell cul-
ture experiments. For the inhibition of cathepsins, a broad-spectrum
cathepsin inhibitor was used (10 μM; Z-FG-NHO-BzME; Merck,
Whitehouse Station, NJ). DMSO was used as negative control.
Quantitative Polymerase Chain Reaction Analysis of
Collagen XVIII Messenger RNA Expression
To analyze the regulation of collagen XVIII expression, total RNA
from PSCs and PCCs were isolated using the RNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s instruc-
tions. Complementary DNA was generated from total RNA using
the QuantiTect Reverse Transcription Kit (Qiagen) with 1 μg of
RNA as a template. Quantitative gene expression was analyzed using
the predesigned TaqMan Gene Expression Assay for Collagen XVIII
(assay ID HS01043433_g1; containing two gene-specific primers
and the probe mix solution) on a 7300 Real-Time PCR System (Ap-
plied Biosystems, Foster City, CA). Polymerase chain reactions were
performed in duplicate, using β-actin as a housekeeping gene. The data
Figure 1. Localization of CD31, α-SMA, and periostin in normal and diseased pancreatic tissues: Immunohistochemical analysis was
carried out using consecutive tissue sections of the normal pancreas. Sections were probed with antibodies against CD31 (A; original
magnification, ×200) for endothelial cells and against α-SMA (B) for smooth muscle cells and PSCs. Analysis of periostin expression in
CP tissues (C–E; original magnification, ×100): The PSCs in the periacinar spaces are marked by their periostin expression (C, arrows).
Note that periostin-positive PSCs do not yet express α-SMA (D), and periostin has not yet been deposited in the periacinar spaces, where
CD31-positive vessels are seen (E, arrows).
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were normalized to the β-actinmessenger RNA (mRNA) level, and the
comparative 2−Ct method (2−deltaCT) was used for analysis.
Statistical Analysis
Graphs were created and statistical analyses were performed using
the GraphPad Prism 4 Software (GraphPad, San Diego, CA). The
percentages of CD31 and α-SMA staining and the results of ELISA
and densitometric analyses are represented as mean ± SEM. TheMann-
Whitney U test or Kruskal-Wallis and Dunn’s multiple comparison
tests were used for comparison of nonparametric data. The level of
statistical significance was set at P < .05.
Results
Microvessel Density Decreases Significantly in the
Diseased Pancreas
In the normal pancreas, there was a fine, homogenous blood supply
to the parenchyma that was seen in the periacinar spaces. Both the
scarce α-SMA positivity and the CD31 expression of the vessels were
seen in the periacinar spaces (Figure 1, A and B, arrows). In CP and
CP-like changes of the PDAC, periostin expression of PSCs preceded
the expression of the typical activation marker (α-SMA) of PSCs (Fig-
ure 1, C and D, arrows). In the periacinar spaces, periostin staining
colocalized with the fine capillary network detected by CD31 positiv-
ity (Figure 1E , arrows). In both CP and PDAC, the invading front of
the activated stroma was marked by expansion of the periacinar spaces,
where myofibroblasts deposited a periostin-rich ECM (Figure 2, A and
B, black arrows). This maximal expression of periostin was not detected
in organized fibrosis (Figure 2A, white single-headed arrow) or in the
preserved parenchyma (Figure 2A, white double-headed arrow). As stro-
mal invasion progressed into the parenchyma, the acini became grad-
ually isolated, and tubular complexes started to appear (Figure 2C ,
arrows). These changes were also accompanied by a gradual decrease
in the vascularity of the periacinar spaces as they became increasingly
fibrotic. The MVD of the normal pancreas, as determined by CD31
expression, was five-fold and four-fold higher than in fibrotic areas of
Figure 2. Site-specific deposition of periostin-rich stroma on the invasive front of the activated stroma in PDAC parallels increased α-SMA
expression of PSCs and decreased vascularity in the diseased pancreas. Compared with both normal parenchyma (A; original magnification,
×50; white double-headed arrow) and organized ECM (white arrow), periostin expression dramatically increased at the interface where the
activated stroma bordered on normal acini. The activation of stromal cells and detection of periostin expression in the CP-like changes
surrounding the cancer occur even in areas where no cancer cells are visible. Although some periostin staining was detected in the inter-
lobar septa (B and C; original magnification, ×200), the strongest expression was detected in the periacinar spaces (B, arrows). Notice the
encasement of acini by the periostin-rich ECM and emergence of tubular complexes (C, arrows; original magnification, ×200). The percent-
age of CD31 (D) and α-SMA (E) staining in normal pancreas, CP, and PDAC tissues is graphically depicted. Results are expressed as mean±
SEM. Evaluation of CD31 (F, G, H) and α-SMA (I, J, K) using consecutive sections of normal (F, I), CP (G, J), and PDAC (H, K) tissues is shown.
500 Hypoxia-Fibrosis Cycle in Pancreatic Cancer Erkan et al. Neoplasia Vol. 11, No. 5, 2009
CP (P < .001) and PDAC (P < .01), respectively (Figure 2D). The sig-
nificant increase of α-SMA expression in fibrotic areas of CP (6.5-fold,
P < .05) and PDAC (8.7-fold, P < .01) compared with that in the
normal pancreas is depicted in Figure 2E . When CP and PDAC tissues
were compared, the medianMVD (+29%) and α-SMA (+33%) expres-
sions of PDAC were higher than those of CP (not significant [n.s.]).
In several peritumoral areas, the number of PSCs was higher than the
number of PCCs (Figure 3A). The number of PSCs generally decreased
in areas where thick bands of organized ECM proteins were deposited,
but α-SMA and CD31 expression increased in a site-specific manner in
the immediate peritumoral stroma (Figure 3, B and C , arrows). Similarly,
in the immediate peritumoral stroma, increased periostin expression co-
localized with the activated PSCs and irregular vessels (Figure 3, D–F).
Hypoxia Increases the Expression of α-SMA and
Secretion of ECM Proteins in PSCs
The expected consequence of decreasing vascularity in the face of
increasing fibrosis is hypoxia. Therefore, we analyzed PSCs’ responses
after 1 day (Figure 4A) and 3 days (Figure 4B) of hypoxia in vitro. Try-
pan blue staining was used to assess PSCs’ viability after hypoxia. The
combination of serum-free medium and hypoxia caused PSCs’ death
only after the fourth day (data not shown). Compared with the nor-
moxic controls, 1 day of hypoxia slightly increased the α-SMA expres-
sion (122 ± 18%, n.s.) and approximately doubled the secretion of all
ECM proteins: periostin (190 ± 61%, n.s.), type I collagen (230 ±
48%, n.s.), and fibronectin (206 ± 57%, n.s.). After 3 days of hypoxia,
the expression of α-SMA significantly increased to 170 ± 34% (P =
.037), and because of increased synthesis, secretion of periostin in-
creased to 213 ± 82% (P = .029). In contrast, the synthesis of type I
collagen and fibronectin was unchanged; thus, the secretion of type I
collagen (95 ± 37%) and fibronectin (92 ± 42%) remained mostly un-
changed compared with matching normoxic samples.
Regulation of VEGF and Endostatin Production of PCCs and
PSCs under Hypoxia
Next, we assessed the effect of hypoxia on the secretion of angio-
genic and antiangiogenic substances by PSCs and PCCs. ELISA was
used to assess VEGF and endostatin secretion. Whereas hypoxic
Panc-1 (198 ± 39%) and SU86.86 (597 ± 47%) SNs contained re-
markably more VEGF than normoxic samples do, there was no ob-
vious increase in the SNs of Colo-357 and MiaPaCa-2 cell lines.
Importantly, PSCs were the most potent VEGF producers under
hypoxia. With a 175 ± 124% increase under hypoxia compared with
normoxic samples, they secreted more than double the amount of
VEGF secreted by the most potent cancer cell (Figure 4C ).
In contrast, hypoxia decreased endostatin secretion in both PCC and
PSC SNs (Figure 4D). Importantly, MiaPaCa-2 and Panc-1 cell lines
secreted more endostatin than PSCs (up to 15-fold) under normoxia.
Although absolute values were reduced under hypoxia, MiaPaCa-2 and
Panc-1 cell lines were also more potent than PSCs (up to 18-fold) in
endostatin production.
Pancreatic Cancer Cell SNs Suppress Endothelial Cell
Growth, Whereas Stellate Cell SNs Increase It
To test if VEGF and endostatin secretion of cultured PCCs and
PSCs reflect their proangiogenic and antiangiogenic potencies in vitro,
Figure 3. Analysis of peritumoral expression of α-SMA, periostin, and CD31: Immunohistochemical analysis on PDAC tissue was per-
formed using anti–α-SMA antibody with hematoxylin counterstaining. Notice the significantly higher number of PSCs compared with
cancer cells (A; original magnification, ×50). A demonstrative example of a highly desmoplastic PDAC is shown (B and C). Notice the
mostly acellular ECM (white double arrow) and the increase in both α-SMA (B, black arrows) and CD31 (C, black arrows) staining in the
peritumoral stroma. Colocalization of α-SMA (D; original magnification, ×100), periostin (E), and CD31 (F) around cancer structures is dem-
onstrated in sections without counterstaining.
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we treated HUVECs with the respective SNs. In accordance with the
ELISA results, all PCC lines suppressed HUVECs’ growth, by −25%
to −92% compared with controls (Figure 5A). This suppression was
consistently less prominent in hypoxic samples for all PCC lines
(−9% to −59%). In contrast, PSCs increased the growth of HUVECs
by up to 47%.
Effects of Pancreatic Cancer–Stellate Coculture on
HUVECs’ Growth
Because the SNs of monocellular cultures of PCCs and PSCs had
opposite effects on HUVECs’ growth, to simulate the in vivo situa-
tion, we assessed the effect of cancer and stellate cells’ coculture SN
on HUVECs’ growth. For this purpose, the two highest endostatin-
producing cancer cell lines (MiaPaCa-2 and Panc-1) were chosen for
coculture experiments. Surprisingly, PSCs could not antagonize the
antiangiogenic effects of PCCs; therefore, the coculture SNs were also
predominantly antiangiogenic (Figure 5B).
Pancreatic Cancer and Stellate Cell Cocultures Increase
Both VEGF and Endostatin Secretion
To elucidate the mechanism of the antiangiogenic effect of the co-
culture SN on HUVECs, we measured the VEGF and endostatin con-
tent of the common SN. Compared with the sum of the individual
controls of PCCs and PSCs, the amount of VEGF secreted in the cocul-
ture SN was significantly higher (P = .005; Figure 6, A and B). Similarly,
there was also a significant (P = .002) increase in endostatin in the cocul-
ture SN beyond the sum of the individual controls (Figure 6, C andD).
Cancer Cells Stimulate Stellate Cells to Secrete More
VEGF, Whereas Stellate Cells Increase the Endostatin
Production of Cancer Cells
To highlight the interaction between PCCs and PSCs, cells were
cross-treated with each other’s SNs. Compared with the sum of the
individual controls, VEGF increased 390% if the stellate cells were
treated with cancer cell SNs (P < .001), whereas endostatin increased
210% if the cancer cells were treated with PSC SNs (P < .001). When
Figure 4. Effect of hypoxia on ECM protein synthesis and secretion of PSCs in vitro and quantification of secreted VEGF and endostatin
in PCC and PSC SNs by ELISA: Sister clones of PSCs were kept under normoxic (N) and hypoxic (H) conditions for 1 (A) and 3 days (B) in
serum-free medium. Matching CLs and SNs (SN) were analyzed by immunoblot analysis to evaluate the synthetic and secretory re-
sponses, respectively. All experiments were performed at least three times, and the results of densitometric analyses are presented
as percent change (mean ± SEM) compared with the matching normoxic control (100%). Immunoblots were consecutively probed with
α-SMA, periostin, type I collagen, fibronectin, and γ-tubulin antibodies. Sister clones of PCCs and PSCs were kept under normoxic and
hypoxic conditions for 24 hours in serum-free medium. The amounts of VEGF (C) and endostatin (D) secreted in the SNs were quantified
by ELISA. The values are expressed normalized to 100,000 cells. The experiments were performed at least three times using different
PSC clones. *P = .037, **P = .0286.
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the sequence of treatment was reversed, the increase in VEGF and en-
dostatin amounts was much less (65% and 26%, respectively) and did
not reach statistical significance (Figure 7, A and B).
Increased Endostatin Production by Cancer Cells Is Not Due to
Increased Synthesis
Because we showed before that PCCs can stimulate PSCs to secrete
VEGF [22], we focused on how PSCs increase the endostatin produc-
tion of cancer cells. When the amount of collagen XVIII mRNA (pre-
cursor of endostatin) was analyzed by quantitative real-time polymerase
chain reaction, MiaPaCa-2 and Panc-1 had 5-fold and 43-fold higher
relative mRNA ratios, respectively, compared with PSC.When the can-
cer cells were treated with PSC SNs, although there was no obvious
increase in MiaPaCa-2 (−11 ± 26%), there was an 89 ± 50% increase
of collagen XVIII mRNA in Panc-1 (data not shown). Because this cell
line–specific (present in Panc-1 and absent in MiaPaCa-2) and modest
increase did not explain the significant increase at the protein level ob-
served in both cell lines, we evaluated whether the increase in endo-
statin was due to augmented cleavage from its precursor.
Both PCCs and PSCs Produce MMP-12 and Cathepsin B
to Cleave Endostatin from Collagen XVIII
It is known that endostatin is cleaved from collagen XVIII by
MMP-12 and cathepsins. Although both cancer cell lines secrete
MMP-12, only 3 of 13 PSC clones secreted detectable amounts of
MMP-12 (Figure 7C ). There was also a slight increase of MMP-12
secreted in the SNs when PCCs and PSCs were cultured together
(Figure 7D). Conversely, higher amounts of cathepsin B were pro-
duced by PSCs (Figure 7E ).
Matrix Metalloproteinases Play a More Prominent Role
in the Cleavage of Endostatin Than Cathepsins
Because no specific MMP-12 inhibitor is available, cells were treated
with a broad-spectrum small-molecule MMP inhibitor that also inhi-
bits MMP-12 activity. Similarly, a broad-spectrum small-molecule ca-
thepsin inhibitor was used, which inhibits cathepsins B, S, and L.
When the cancer cells were treated with the inhibitors, MMP inhibi-
tion resulted in a 65% reduction of endostatin production (P < .001),
whereas cathepsin inhibition had no effect (Figure 8A). Because endo-
statin production by PSC was negligible, we tested the effect of the in-
hibitors when the PSCs were treated with cancer cell SNs. Matrix
metalloproteinase inhibition resulted in a 49% reduction of endo-
statin production, whereas inhibition of cathepsins resulted in a 67%
(P < .001) reduction of endostatin (Figure 8B). Next, we assessed the
effect of the inhibitors during coculture of cancer and stellate cells.
Compared with the sum of the controls, there was a 277 ± 36% in-
crease in endostatin production in the common SN (P < .001). When
the inhibitors were used, there was a 204% reduction by MMP inhi-
bition (P < .05), whereas inhibition of cathepsin resulted only in a
Figure 5. Assessment of HUVEC growth after treatment with PCC and PSC SNs: HUVECs were seeded in 96-well plates (5000 cells per
well) in complete endothelial cell growth medium (100 μl per well). Twenty-four hours later, 100 μl of cancer cell or stellate cell or co-
culture SN was added to the cells. Forty-eight hours later, cell growth was assessed by MTT assay corrected for day 0. The experiments
were performed at least nine times using three different HUVEC clones and three different PSC clones. The effect of four different
cancer cell lines and PSC SNs on HUVEC growth is shown in panel (A). The effect of the common SN after coculture of MiaPaCa-2
and Panc-1 with PSC is shown in panel (B). The growth-inhibiting or growth-promoting effects of SNs on HUVECs are shown as percent
change of the control (0%).
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24% reduction (Figure 8C ). At the doses used in the experiments,
neither drug had any negative effect on PSCs or PCCs growth (data
not shown).
Discussion
Angiogenesis and ECM production are interrelated physiologic re-
sponses in wound healing and tissue regeneration, processes in which
several molecules have bimodal functions. Recently, it has been reported
that hypoxic induction of the key angiogenic molecule—VEGF—
increased hepatic stellate cell activity, motility, and type I collagen syn-
thesis [25]. Like their counterparts in the liver, PSCs also have strong
proangiogenic attributes through secretion of VEGF, basic fibroblast
growth factor, periostin, and type I collagen [3,4,22,26,27]. Periostin,
which is known to induce angiogenesis in colon and breast cancers,
is uniquely secreted by PSCs in the pancreas [4,26,27]. Like type I colla-
gen, periostin promotes endothelial cell growth andmotility and perpet-
uates the fibrogenic activity of PSCs [4,26,27].
Unlike in acute pancreatitis, where PSCs’ activity is transient, PSCs
of the CP and pancreatic cancer–associated stroma maintain their acti-
vated phenotype and secrete excessive amounts of ECM proteins, lead-
ing to organ fibrosis and hypoxia [4,21,24,28,29]. In vitro, hypoxia
strongly induces both periostin and VEGF secretion while suppressing
endostatin production of PSCs. As expected, PSCs promote endothe-
lial cell growth under both normoxic and hypoxic conditions.
What remains paradoxical is why both CP and PDAC are hypo-
vascular and therefore hypoxic compared with normal tissues [21]. It
seems likely that abnormal deposition of the stromal proteins by
PSCs in CP and PDAC distorts the normal parencyhmal architecture
and interferes with oxygen diffusion into the tissues. We have previ-
ously shown that there is very scarce expression of periostin in the
normal pancreas, but once activated by cancer cells, PSCs remain fibro-
genic and secrete abundant type I collagen and fibronectin because
of an autocrine-positive feedback loop running over periostin [4]. We
now show that: 1) although it is less than that in cancer, there is also
a remarkable increase of periostin in CP compared with that in the nor-
mal pancreas; 2) this highly site-specific periostin overexpression is
found in the periacinar spaces on the invading front of the activated
stroma, where acini are isolated by abnormal deposition of ECM pro-
teins; 3) hypoxia increases PSCs’ activity as well as secretion of periostin,
type I collagen, and fibronectin; and 4) because periostin expression of
PSCs precedes α-SMA expression, it may be used as an early activation
marker for PSCs in vivo, as they transform from quiescent PSCs into
activated myofibroblasts. Viewed in combination, these observations
may explain why CP-like changes in PDAC progress ahead and beyond
of cancer cells [13,24].
Figure 6. Quantification of VEGF and endostatin secretion in pancreatic cancer–stellate cell coculture SNs by ELISA: PSC (200,000 cells
per well) and PCC (400,000 cells per insert, 1-μm pore size) were cocultured for 24 hours in serum-free medium. The amount of VEGF (A)
and endostatin (C) secreted in the common SN was quantified by ELISA. The experiments were repeated at least twice using different
PSC clones. In comparison to the mathematical sum of the individual controls (PCC + PSC), the increase of VEGF (B) and endostatin (D)
in the common SN after coculture of MiaPaCa-2 and Panc-1 with PSCs is expressed in percentages.
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Within the confines of a fibrotic tumor stroma, capillary perfusion
decreases as tissue pressure increases, because of the increasing number
of cancer cells [15,30,31]. Similarly, secondary to excessive PSCs’
growth and ECM deposition, the capillaries are probably compressed,
hindering blood perfusion of the normal pancreas. Therefore, on the
invasive front of the activated stroma, continuous activation of PSCs
in the periacinar spaces and the subsequent deposition of ECM pro-
teins around a fine capillary network may physically cause tissue hyp-
oxia by hindering the blood circulation and oxygen diffusion. In line
with this argument, PSCs’ activity (α-SMA, periostin) increased sig-
nificantly in the diseased pancreas, with excessive deposition of ECM
in the periacinar spaces, whereas MVD decreased reciprocally.
It is becoming clearer that tumors grow by co-opting their neigh-
boring stromal cells and host vessels, which then provide the tumors
with environmental and vascular support [4,10,19,32]. According to
Yancopoulos et al. [10], in response to tumor co-option, the host vessels
mount a defensive response. Sensing inappropriate co-option, they re-
gress, which results in a secondarily avascular and hypoxic tumor [10].
In our study, as demonstrated in the literature, organ fibrosis (CP)
was associated with a rarefication of the microvasculature [15]. In
contrast, however, although solid tumors are known to be typically
more vascularized than normal tissues [7,19], PDAC is a hypovascular
and hypoxic tumor. One possible explanation is that PCCs produce
remarkable amounts of endostatin, in vitro and in vivo, even under
hypoxia. Endostatin is a 20-kDa C-terminal fragment of collagen XVIII
that specifically inhibits endothelial proliferation and potently inhibits
angiogenesis [28]. It is cleaved from its precursor by MMP-12 and ca-
thepsins such as B and L [33–35]. We have previously shown by IHC
that PDAC cells and peritumoral stromal cells express MMP-12 [36].
Now, we show that PSCs modulate endostatin production of PCCs
mostly by cleaving endostatin from its precursor. When PSCs were co-
cultured with PCCs or when PSC SN was used to incubate, there was
Figure 7. Quantification of secreted VEGF and endostatin by ELISA after exchange of SNs between PSCs and PCCs and assessment of
MMP-12 and cathepsin B production by PSCs and PCCs: PSC (200,000 cells per well) and PCC (400,000 cells per well) were cultured in
serum-free medium. After 24 hours, the individual SNs were exchanged and kept on the reciprocal cells for another day. PCC > PSC
denotes cancer cell SN added to PSC; PSC > PCC denotes PSC SN added to cancer cells. In the control wells, serum-free medium was
used to incubate the cells for 24 hours. The amount of VEGF (A) and endostatin (B) secreted was quantified by ELISA. In the control
columns (PCC + PSC), the VEGF and endostatin produced by PCCs in 24 hours (black column) are mathematically added to the amount
produced by the PSCs (white column above the black). The experiments were repeated three times using different PSC clones. Immu-
noblot analysis was used to measure the MMP-12 in the CLs and in the SN of cells (C). Five nanograms of MMP-12 was loaded to the
first column as positive control (AG902; Millipore). MMP-12 secreted by cocultured PCC and PSC is shown (D). Secreted cathepsin B
was quantified by ELISA (E). Error bars, SEM.
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an increase in the final endostatin amount, as it was mainly produced
by PCCs (without a concomitant rise in collagen XVIII mRNA expres-
sion) through cleavage of collagen XVIII by PSC- and PCC-derived
MMP-12. This is in line with our and with other groups’ previous ob-
servations that cancer cells induce MMP production of PSCs around
them [36].
Nonetheless, in comparison to CP tissues, PDAC tissues expressed
33% more α-SMA and had a 29% higher MVD, although these dif-
ferences were statistically not significant when the overall expressions
were compared. The changes were mostly seen in the immediate
peritumoral reactive stroma, where a consistent increase beyond their
overall expression was found in α-SMA, periostin, and CD31 staining.
Therefore, several lines of evidence suggest that PDAC at least partially
induces neoangiogenesis by co-opting PSCs: 1) periostin is a proangio-
genic molecule secreted by PSCs [4,26,27]; 2) PCCs activate PSCs
and increase their periostin production [3,4]; 3) under hypoxia, acti-
vated PSCs secrete higher amounts of VEGF than the cancer cells do;
4) PCC SNs suppress HUVECs’ growth, whereas PSC SNs promote it;
and 5) the disorganized tumor vessels are not seen in the fibrotic part of
the stroma but mostly in the reactive stroma around the cancer cells.
Probably, PCCs co-opt PSCs by initially creating local hypoxia with
their antiangiogenic attributes. In response to hypoxia, both cancer cells
and activated stellate cells then produce excessive VEGF, creating a lo-
cally proangiogenic microenvironment that facilitates endothelial cell
recruitment mostly in the immediate vicinity of the cancer cells. Never-
theless, the same inducers of angiogenic PSC responses (activation by
cancer, hypoxia) also elicit a stronger fibrogenic response which ulti-
mately creates a fibrotic/hypoxic tissue (Figure 9).
Stellate cells augment pancreatic tumor development and possibly
increase their metastatic spread in animal models [3,32,37]. It is still
Figure 8. Quantification of secreted endostatin by ELISA after treatment with small-molecule broad-spectrum inhibitors of MMP and
cathepsin: MiaPaCa-2 and Panc-1 (400,000 cells per well) were cultured alone (A) or cocultured with PSCs (C) for 24 hours in the pres-
ence of a small-molecule broad-spectrum MMP inhibitor (50 μM), cathepsin inhibitor (10 μM), or DMSO as control. To assess their effect
on the cleavage of endostatin from the secreted collagen XVIII by cancer cells, inhibitors were added to the cancer cell SNs that were
used to incubate PSC (200,000 cells per well) for 24 hours (B). Changes are expressed as percentages compared with the appropriate
control (sum of the DMSO controls of PCC and PSC: PCC + PSC, 100%). PCC & PSC denotes the coculture of PCC and PSC in the
presence of DMSO (control), small-molecule broad-spectrum MMP inhibitor (50 μM), or cathepsin inhibitor (10 μM). Error bars show the
SEM. The experiments were repeated using five different PSC clones and two different cancer cell lines. The amount of endostatin
secreted was quantified by ELISA.
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unknown by which mechanisms PSCs contribute to this excessive
tumor growth and dissemination. One possible explanation could
be increased angiogenesis. Here, we used VEGF and endostatin as
surrogate markers for proangiogenic and antiangiogenic attributes
of PSCs and PCCs. Nevertheless, it would be an oversimplification to
reduce neoangiogenesis to a balance between VEGF and endostatin
only and disregard several other proangiogenic and antiangiogenic
factors known to be secreted by cancer cells, stellate cells, and inflam-
matory cells. For example, the SNs of the PSCs obtained under nor-
moxic conditions (which contain less VEGF and more endostatin)
increased HUVECs’ growth more than the hypoxic ones. Although
statistically insignificant, this unexpected effect underlines the pres-
ence of other possible factors affecting HUVECs’ growth and needs
further clarification.
In conclusion, PDAC is an extremely scirrhous and hypoxic tumor
due to both fibrogenic effects of PSCs and antiangiogenic effects of
cancer cells. Pancreatic stellate cells can produce remarkable amounts
of VEGF and modulate the amount of endostatin produced by cancer
cells. Therefore, in contrast to expectations, localized increase of MVD
around cancer structures is not a function of cancer cells but is prob-
ably a result of the proangiogenic attributes of peritumoral PSCs.
Nonetheless, deposition of excessive ECM proteins in the periacinar
spaces and perpetuation of PSCs’ activity under hypoxia overwhelms
PSCs’ local proangiogenic properties, creating tissue hypoxia in CP and
pancreatic cancer (Figure 9). These findings may help explain why
antiangiogenic therapies generally fail in PDAC and suggest that novel
therapeutic approaches targeting cancer-stroma interactions could be
explored [23].
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